ADC Medical Safety and Pharmacovigilance
Because ADC patient safety requires focused oversight ADC Medical Safety and Pharmacovigilance
When ADC safety expertise is critical and internal capacity is limited, DES Pharma acts as a trusted extension of your team. We support medical safety leadership, pharmacovigilance oversight, and risk management across development and post-approval stages, with attention to the safety issues most relevant to antibody-drug conjugates.
Phase 1/2:
Proactive ADC safety monitoring, signal detection, risk characterization, and dose-management support during early development.
Learn more ▾
- Establish ADC medical safety strategy
- Safety input for study protocols, investigator brochures, and dose-escalation decisions
- Medical monitoring plans for expected ADC toxicities
- Signal detection and early risk characterization
- Dose interruption, dose reduction, rechallenge, and discontinuation guidance
- Safety review support for expansion cohorts and combination studies
- Aggregate safety review and cross-functional communication
- Independent data monitoring committee support where appropriate
- Regulatory safety input for development-stage submissions
Phase 3/Post-Authorization
Late-stage and post-approval safety oversight that supports benefit-risk evaluation, regulator expectations, and long-term product use.
Learn more ▾
- Continuous risk characterization and safety trend review
- Aggregate reports and benefit-risk evaluation support
- Risk mitigation planning and implementation
- Global and regional safety document support, including RMPs, CCDS updates, and labeling changes
- Safety support for expanded indications and broader populations
- Independent committee support where needed
- Post-authorization safety planning and regulator response support
Pharmacovigilance
Global ADC pharmacovigilance support designed for compliant, inspection-ready operations across the product lifecycle, from case handling through governance and system oversight.
Learn more ▾
- Pharmacovigilance agreements
- Case intake, medical review, reporting, and oversight
- Medical review and follow-up workflows
- Quality systems, training, and KPI oversight
- Quality systems, training, and KPI oversight
- EU QPPV and PSMF support where relevant
- Vendor oversight for outsourced pharmacovigilance activities
- Readiness for larger Phase 3 and commercial safety operations
Our team combines medical judgment, pharmacovigilance oversight, and practical ADC development experience to support safer decisions across the product lifecycle.
Get Started
Advance Your Drug Program
with Confidence
Start building reliable, high-quality drug development programs today.